Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Profound Medical (PROF : NSDQ)

• Company Description    Profound Medical Corp. is a medical technology company. It is focused on a therapeutics platform which provides the precision of real-time Magnetic Resonance Imaging technology for the incision-free ablation of diseased tissue. The company principally commercialized the TULSA-PRO(R) and Sonalleve(R) platforms. Profound Medical Corp. is based in Mississauga, Canada. Number of Employees: 142

• Price / Volume Information    Yesterday's Closing Price: $7.87 Daily Weekly Monthly 20 Day Moving Average: 156,000 shares Shares Outstanding: 35.37 (millions) Market Capitalization: $278.36 (millions) Beta: 0.54 52 Week High: $7.99 52 Week Low: $3.76 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 16.59% 16.79% 12 Week 18.70% 16.79% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2400 SKYMARK AVENUE UNIT 6 - MISSISSAUGA,A6 L4W 5K5 CAN ph: 64-7476-1350 fax: 64-7847-3739 skilmer@profoundmedical.com http://www.profoundmedical.com

• General Corporate Information    Officers Arun Menawats - Chief Executive Officer and Director Rashed Dewan - Chief Financial Officer Brian Ellacott - Director Cynthia Lavoie - Director Murielle Lortie - Director Peer Information Profound Medical (GSAC) Profound Medical (CASI) Profound Medical (ALCD.) Profound Medical (OMNN) Profound Medical (CGPI.) Profound Medical (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 74319B502 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/05/26 Share - Related Items Shares Outstanding: 35.37 Most Recent Split Date: (:1) Beta: 0.54 Market Capitalization: $278.36 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.27 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.95 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 7.39 Price/Cash Flow: - Price / Sales: 19.47 EPS Growth vs. Year Ago Period: 31.58% vs. Previous Quarter: 50.00% Sales Growth vs. Year Ago Period: 86.76% vs. Previous Quarter: 139.21% ROE 12/31/25 - - 09/30/25 - -86.18 06/30/25 - -89.74 ROA 12/31/25 - - 09/30/25 - -70.55 06/30/25 - -73.06 Current Ratio 12/31/25 - - 09/30/25 - 4.18 06/30/25 - 8.53 Quick Ratio 12/31/25 - - 09/30/25 - 3.34 06/30/25 - 7.07 Operating Margin 12/31/25 - - 09/30/25 - -275.16 06/30/25 - -343.97 Net Margin 12/31/25 - - 09/30/25 - -275.16 06/30/25 - -343.97 Pre-Tax Margin 12/31/25 - - 09/30/25 - -275.25 06/30/25 - -343.61 Book Value 12/31/25 - - 09/30/25 - 1.06 06/30/25 - 1.31 Inventory Turnover 12/31/25 - - 09/30/25 - 0.54 06/30/25 - 0.53 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.11 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 10.21

Powered by Zacks Investment Research ©